Biodistribution of iodine-125 labeled monoclonal antibody/interleukin- 2 immunoconjugate in athymic mice bearing human tumor xenografts

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2650-2655

  Nakamura, Kayoko ^a   Kubo, Atsushi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Carcinoembryonic antigen; Iodine 125 label; Monoclonal antibody interleukin 2 conjugate; Targeting

Indexed keywords

ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 125; MONOCLONAL ANTIBODY I 125; MONOCLONAL ANTIBODY ZCE 025; RECOMBINANT INTERLEUKIN 2; SERUM ALBUMIN I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL PERMEABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STOMACH CARCINOMA; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

EID: 0031471211     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2650::aid-cncr41>3.0.co;2-8     Document Type: Conference Paper

References (24)

1. Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer 1990;50:159-63.
2. Gridley D, Ewart K, Cao J, Stickney D. Hyperhthermia enhances localization of In-111-labeled hapten to bifunctional antibody in human colon tumor xenografts. Cancer Res 1991;51.
3. Neuwelt E, Specht H, Barnett P, Dahlborg SA, Milley A, Larson SM, et al. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 1987;20:885-95.
4. Shults K, Badger C, Dombi G, Greenberg P, Bernstein I. Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissue in mice bearing SL-2 thymoma. J Natl Cancer Inst 1992;84:109-13.
5. Leberthon B, Khawli L, Alauddin M, Miller GK, Charak BS, Mazumder A, et al. Enhancement tumor uptake of macromolecules induced by a novel vasoactive interleukin-2 immunoconjugate. Cancer Res 1991;51:2694-8.
6. DeNardo G, DeNardo S, Kukis D, Diril H, Suey C, Mears C. Strategies for enhancement of radioimmunotherapy. Nucl Med Biol 1991;18:636-40.
7. Nakamura K, Kubo A. Effect of interleukin-2 on the biodistribution of technetium-99m-labelled anti-CEA monoclonal antibody in mice bearing human tumour xenografts. Eur J Nucl Med 1994;21(9):924-9.
8. Thakur M, DeFulvio J, Tong J, John E, McDevitt M, Damjanov I. Evaluation of biological response modifiers in the enhancement of tumor uptake of technetium-99m labeled macromolecules. J Immunol Methods 1992;152:209-16.
9. Hennigan T, Begent R, Allen-Mersh T. Histamine, leukotriene C4, and interleukin-2 increase antibody uptake into a human carcinoma xenograft model. Br J Cancer 1991; 64:872-4.
10. Khawli L, Miller G, Epstein A. Effect of seven new vasoactive immunoconjugatees on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994;73(3):824-31.
11. Damle N, Doyle L, Bender J. Interleukin-2-activated human lymphocytes exhibit enhanced adhesion to normal vascular enodothelial cells and cause their lysis. J Immunol 1987;138:1779-85.
12. Rosenblum M, Cheung L, Murray J, Barthlomew R. Antibody-mediated delivery of tumor necrosis factor (TNF-a): improvement of cytotoxicity and reduction of cellular resistance. Cancer Comm 1991;3:21-7.
13. Buchegger F, Haskell C, Schreyer M, Scazziga B, Randin S, Carrel S, et al. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 1983;158:413-27.
14. Hojo H. Establishment of cultured cell lines of human stomach gastric origin and their morphological characteristics. Niigata Igakukai Zasshi 1977;91:737-63.
15. Harlow E, Lane D. Labeling antibodies: Chloramine T. In: Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988:328-9.
16. Harlow E, Lane D. Labeling antibodies: Iodogen coated tube. In: Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988:330-1.
17. Harlow E, Lane D. Labeling antibodies: Lactoperoxidase labeling of antibodies. In: Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988:335-7.
18. Nakamura K, Kubo A, Hashimoto S. Enhanced tumor targeting and pharmacokinetics change of monoclonal antibody by interfeon. Antibody Immunoconj Radiopharm 1991;4(4):847-57.
19. Mazumder A, Rosenberg S. Successful immunotherapy of natural killer resistant established pulmonary melanoma metastasis by the intravenour adoptive transfer of synergeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 1984;159:495-507.
20. Talmadge J, Phillips H, Schinder J, Tribble H, Pennington R. Systematic preclinical study on the therapeutic properties of recombinant human interleukin-2 for the treatment of metastatic disease. Cancer Res 1987;47:5725-32.
21. Lotze M. In vivo administration of purified human interleukin-2. J Immunol 1985;135:2865-75.
22. Baxter L, Jain R, Svensjo E. Vascular permeability and interstitial diffusion of macromolecules in the hamster cheek pouch: effect of vasoactive drugs. Microvasc Res 1987; 34:336-48.
23. Pieterz G, Smyth M, Kanellos J, Cunningham Z, Sacks N, McKenzie I. Preclinical and clinical studies with a variety of immunoconjugates. Antibody Immunoconj Radiopharm 1988;1:79-103.
24. Becker J, Varki N, Gillies S, Furukawa K, Reisfeld R. An antibody-interleukin-2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996;93:7826-31.